Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform

Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare's Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases and the development of novel therapies. Earlier this year, it was instrumental in finding a new target for breast cancer. In May, GNS published data in the American Association for Cancer Research's (AACR) journal Cancer Research in which they announced the discovery of novel targets, including TRIB1, which had positive implications for the treatment of triple-negative breast cancer. In June, it was announced that the company would be teaming up with Genentech to improve the capability to clarify disease mechanisms, recognize new targets, and diagnose patient populations more accurately.